New asthma drug APG777 enters early safety testing

NCT ID NCT06920901

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 19 times

Summary

This early-stage study tests a new drug called APG777 in 31 adults with mild-to-moderate asthma. The main goal is to check if the drug is safe and how the body handles it. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood over about a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site

    San Jose, California, 95117, United States

  • Investigational Site

    Torrance, California, 90505, United States

  • Investigational Site

    Normal, Illinois, 61761, United States

  • Investigational Site

    Kansas City, Missouri, 66160, United States

  • Investigational Site

    Edmond, Oklahoma, 73034, United States

  • Investigational Site

    Philadelphia, Pennsylvania, 19140, United States

  • Investigational Site

    Pittsburgh, Pennsylvania, 15241, United States

  • Investigational Site

    Bradford, West Yorkshire, BD9 6RJ, United Kingdom

  • Investigational Site

    Manchester, M23 9QZ, United Kingdom

  • Investigational Site

    La Jolla, California, 92037, United States

  • Investigational Site

    Long Beach, California, 90808, United States

Conditions

Explore the condition pages connected to this study.